Both in Biotechnology
ADMA Biologics vs Beam Therapeutics
Over the past year ADMA returned −27.7% and BEAM returned +8.6%; their daily moves had a correlation of 0.23.
ADMA −27.7% BEAM +8.6%Growth of $1, one year, split-adjusted
| Metric | ADMA | BEAM |
|---|---|---|
| Price | $11.11 | $26.33 |
| Market cap | $2.49B | $2.72B |
| Today | +0.45% | +1.78% |
| 1 month | +9.9% | +2.6% |
| 6 months | +8.4% | −8.9% |
| Year to date | −39.1% | −5.0% |
| 1 year | −28.2% | +5.3% |
| Revenue growth (YoY) | +2.0% | −94.2% |
| Gross margin | 69.4% | 100.0% |
| Net margin | 30.4% | −25036.3% |
| P/E (TTM) | 14.7× | — |
| Price / sales | 4.9× | 17.4× |
| Net cash | -$60.6M | $1.05B |
| Dividend yield | — | — |
| Volatility (60d) | 38.5% | 63.4% |
| Short % of float | 9.1% | 32.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).